Payment overview · 2025
General Payments
$82,629.13
327 reported records · 46 companies
Healthcare provider profile · identity verified
Perminder Bhatia, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · FRESNO, CA · NPI 1013002328
Verified facts
What the public records show
CMS Open Payments records show Perminder Bhatia, MD received $82,629.13 in general payments during 2025 across 327 reported records.
Lilly USA, LLC accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 54 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Briviact, Dysport, Gamunex-C, Gocovri, Ingrezza, Nurtec Odt, Qulipta, Rexulti, Ubrelvy, Zeposia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ubrelvy by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Rytary by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Privigen as an associated drug or biological on 464 records involving 289 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Privigen by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZEPOSIA as an associated drug or biological on 9581 records involving 2490 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Zeposia by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Gamunex-C by this doctor in 2024.
Ipsen Biopharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Dysport as an associated drug or biological on 4791 records involving 2152 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Dysport by this doctor in 2024.
Ipsen Innovation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Dysport as an associated drug or biological on 11 records involving 5 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Dysport by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Rexulti by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gocovri as an associated drug or biological on 3202 records involving 1029 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gocovri by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Xcopri by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Gammagard Liquid by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17,958.45 | 21.7% | 17 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $14,489.29 | 17.5% | 28 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14,332.46 | 17.4% | 22 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14,176.31 | 17.2% | 42 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $12,337.05 | 14.9% | 17 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $3,881.31 | 4.7% | 4 | 2025 |
| Ipsen Innovation | Unresolved — no canonical attribution shown | $887.09 | 1.1% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $521.87 | 0.6% | 20 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $256.52 | 0.3% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $254.83 | 0.3% | 7 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $241.36 | 0.3% | 13 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $238.08 | 0.3% | 16 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$235.98 | 0.3% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $185.96 | 0.2% | 11 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$185.40 | 0.2% | 8 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $175.54 | 0.2% | 9 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $160.45 | 0.2% | 7 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $159.72 | 0.2% | 7 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $158.33 | 0.2% | 9 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $143.33 | 0.2% | 7 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $139.23 | 0.2% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $132.65 | 0.2% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $130.80 | 0.2% | 6 | 2025 |
| Virtus Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $125.60 | 0.1% | 2 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $125.54 | 0.1% | 4 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $113.47 | 0.1% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $103.01 | 0.1% | 4 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $100.42 | 0.1% | 4 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $96.05 | 0.1% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $84.67 | 0.1% | 4 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $55.45 | 0.1% | 3 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $52.64 | 0.1% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $48.06 | 0.1% | 2 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $44.51 | 0.1% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $38.75 | 0.1% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $38.72 | 0.1% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $36.28 | 0.0% | 2 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.60 | 0.0% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $26.09 | 0.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.58 | 0.0% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $22.82 | 0.0% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.07 | 0.0% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $17.33 | 0.0% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $16.80 | 0.0% | 1 | 2025 |
| NEUROPACE, INC. | Unresolved — no canonical attribution shown | $14.41 | 0.0% | 1 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $14.25 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $39,705.00 | 22 |
| Honoraria | $13,838.00 | 5 |
| Compensation for serving as faculty or as a speaker for a medical education program | $10,832.50 | 9 |
| Food and Beverage | $7,159.60 | 274 |
| Consulting Fee | $7,095.00 | 6 |
| Travel and Lodging | $3,929.04 | 10 |
| Education | $69.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17,958.45 | 17 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $14,572.36 | 32 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $14,321.41 | 21 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $12,337.05 | 17 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $8,376.22 | 23 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $6,925.94 | 23 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $3,881.31 | 4 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $256.52 | 9 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $254.83 | 7 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $243.94 | 11 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $241.36 | 13 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $238.08 | 16 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $185.96 | 11 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $185.40 | 8 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $158.33 | 9 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $157.14 | 6 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $154.72 | 4 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $149.74 | 6 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $143.33 | 7 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $132.65 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $130.80 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $130.80 | 6 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $126.93 | 8 | 2025 |
Source payment records
|
|||||
| LEVORPHANOL TARTRATE Normalized: levorphanol tartrate |
Drug | Virtus Pharmaceuticals LLC | $125.60 | 2 | 2025 |
Source payment records
|
|||||
| ONGENTYS Normalized: ongentys |
Drug | Amneal Pharmaceuticals LLC | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $113.47 | 4 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $103.01 | 4 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $100.42 | 4 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $92.47 | 5 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $74.16 | 3 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $66.82 | 3 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | MDD US Operations, LLC | $65.54 | 4 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $57.88 | 2 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc. | $55.45 | 3 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $52.64 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $49.05 | 2 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $48.06 | 2 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $38.75 | 2 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $38.72 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $36.28 | 2 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $26.60 | 1 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $26.09 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $26.09 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $26.06 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.58 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $23.76 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $22.82 | 1 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| RNS Neurostimulator Kit Normalized: rns neurostimulator kit |
Device | NEUROPACE, INC. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $11.05 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $10.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 47 | exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Dysport dysport |
2025 | Dysport | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gocovri gocovri |
2025 | Gocovri | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 85 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZEPOSIA zeposia |
2025 | Zeposia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
47 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
203 | 36 |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Privigen open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 289 recipient NPIs · example record 1232339064 |
Privigen · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ZEPOSIA open payments reported associated product |
CMS Open Payments — General Payments 9581 supporting records · 2490 recipient NPIs · example record 1184377823 |
Zeposia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Ipsen Biopharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | Dysport open payments reported associated product |
CMS Open Payments — General Payments 4791 supporting records · 2152 recipient NPIs · example record 1208821659 |
Dysport · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Ipsen Innovation Exact reporting entity; no affiliate inference |
2025 | Dysport open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 5 recipient NPIs · example record 1214556681 |
Dysport · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
85 | 19 |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Gocovri open payments reported associated product |
CMS Open Payments — General Payments 3202 supporting records · 1029 recipient NPIs · example record 1241843637 |
Gocovri · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
85 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
73 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 1140 | 375 |
| Donepezil Hcl | Donepezil Hcl | 493 | 189 |
| Gabapentin | Gabapentin | 330 | 110 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 305 | 93 |
| Rytary | Carbidopa/Levodopa | 203 | 36 |
| Pregabalin | Pregabalin | 128 | 31 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 127 | 34 |
| Clonazepam | Clonazepam | 126 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 119 | 40 |
| Levetiracetam | Levetiracetam | 101 | 37 |
| Propranolol Hcl | Propranolol Hcl | 99 | 26 |
| Lacosamide | Lacosamide | 89 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 89 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 88 | 36 |
| Rexulti | Brexpiprazole | 85 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 22 |
| Tramadol Hcl | Tramadol Hcl | 82 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 75 | 21 |
| Primidone | Primidone | 73 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 73 | 29 |
| Xcopri | Cenobamate | 73 | suppressed |
| Lorazepam | Lorazepam | 68 | 37 |
| Topiramate | Topiramate | 65 | 19 |
| Emgality Pen | Galcanezumab-Gnlm | 61 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 19 |
| Rasagiline Mesylate | Rasagiline Mesylate | 52 | 17 |
| Nortriptyline Hcl | Nortriptyline Hcl | 50 | 14 |
| Botox | Onabotulinumtoxina | 47 | 21 |
| Prednisone | Prednisone | 47 | 20 |
| Aripiprazole | Aripiprazole | 44 | 12 |
| Amantadine | Amantadine Hcl | 42 | 15 |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 41 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 13 |
| Baclofen | Baclofen | 36 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 35 | suppressed |
| Alprazolam | Alprazolam | 33 | suppressed |
| Levetiracetam Er | Levetiracetam | 33 | 13 |
| Lamotrigine | Lamotrigine | 32 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 29 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 27 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 27 | 11 |
| Ingrezza | Valbenazine Tosylate | 26 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 24 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 23 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Briviact | Brivaracetam | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 19 | suppressed |
| Ubrelvy | Ubrogepant | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Fycompa | Perampanel | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Droxidopa | Droxidopa | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Neupro | Rotigotine | 17 | suppressed |
| Dysport | Abobotulinumtoxina | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Entacapone | Entacapone | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Gocovri | Amantadine Hcl | 12 | suppressed |
| Kesimpta Pen | Ofatumumab | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Zeposia | Ozanimod Hydrochloride | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Dalfampridine Er | Dalfampridine | 11 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $82,629.13 · 327 records | Lilly USA, LLC | ACTHAR, AMVUTTRA, AUSTEDO XR, Auvelity, BOTOX, BRIUMVI, Bafiertam, Briviact, CREXONT, Dysport, EPIDIOLEX, Fintepla, Gamunex-C, Gocovri, HYQVIA, Hizentra, INBRIJA, INGREZZA, KESIMPTA, KISUNLA, LEQEMBI, LEVORPHANOL TARTRATE, Motpoly XR, NUPLAZID, NURTEC ODT, Nayzilam, ONGENTYS, Ocrevus Zunovo, PANZYGA, PONVORY, PURIFIED CORTROPHIN GEL, QULIPTA, Qelbree, RELISTOR, REXULTI, RNS Neurostimulator Kit, Rystiggo, Symbravo, TRINTELLIX, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, WAKIX, Xeomin, ZAVZPRET, ZEPOSIA | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error